|
 |
EszopicloneThis page contains recent news articles, when available, and an overview of Eszopiclone but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Eszopiclone (when available) Eszopiclone is a nonbenzodiazepine hypnotic, pyrrolopyrazine derivative of the cyclopyrrolone class and is indicated for the short-term treatment of insomnia. While Eszopiclone is a hypnotic agent with a chemical structure unrelated to benzodiazepines, barbiturates, or other drugs with known hypnotic properties, it interacts with the gamma-aminobutyric acid-benzodiazepine (GABABZ) receptor complex. Subunit modulation of the GABABZ receptor chloride channel macromolecular complex is hypothesized to be responsible for some of the pharmacological properties of benzodiazepines, which include sedative, anxiolytic, muscle relaxant, and anticonvulsive effects in animal models. Eszopiclone binds selectively to the brain alpha subunit of the GABA A omega-1 receptor. For the treatment of insomnia Mechanism Of Action: The mechanism of action of Eszopiclone is not completely understood. It is thought that Eszopiclone acts on the benzodiazepine receptors and interacts with GABA-receptor complexes. News Articles on Eszopiclone Sepracor gets patent term extension for Lunesta - Dec 22, 2009 6444673, which is a composition of matter patent that covers the human drug product Lunesta (eszopiclone), received a patent term extension under 35 USC ... pharmabiz.com Sepracor gets extension of Lunesta patent protection - Dec 18, 2009 By Lisa Eckelbecker TELEGRAM & GAZETTE STAFF WORCESTER — US patent authorities have extended the period during which drug maker Sepracor Inc. may ... Worcester Telegram Zolpidem: Drug Whys - Dec 16, 2009 An agent similar to zolpidem entered the pharmaceutical market in 2005: eszopiclone (Lunestaâ„¢ manufactured by Sepracor – US). Eszopiclone has the advantage ... EMS1.com 불면ì¦?약 '루네스타' 美 특허기간 2ë…„ 연장 - Dec 21, 2009 ...ì?¼ë³¸ 다ì?´ë‹›í?°ìŠ¤ë¯¸í† ëª¨ì œì•½ì?˜ 불면ì¦? ì¹˜ë£Œì œ '루네스타'(Lunesta, eszopiclone)ê°€ 미êµì—?ì„œ 특허기간ì?„ 연장받았다. 다ì?´ë‹›í?°ìŠ¤ë¯¸í† 모는 ë¯¸êµ ìž?회사ì?¸ 세프ë?¼ì½”ê°€ ... 디지틀보사 大日本ä½?å?‹è£½è–¬ã€?セプラコール社ã?®ä¸?çœ ç—‡æ²»ç™‚è–¬ã?®ç‰¹è¨±æœŸé–“延長をèª?ã‚?る通知å?—é ˜ - Dec 17, 2009 ...Ａｄï½?ï½?ｓã€?以下「セプラコール社ã€?）ã?¯ã€?セプラコール社ã?Œä¸?çœ ç—‡æ²»ç™‚è–¬ã?¨ã?—ã?¦è²©å£²ã?—ã?¦ã?„る「ＬＵＮＥＳＴＡ（Ｒ）ã€?（一般å??：ｅｓｚï½?ï½?ｉｃｌï½?ｎｅ）をカãƒ?ー ... 日本経済新聞 (プレスリリース) 任百鸣：è°?是“梦游凶案â€?的真æ£æ?€æ‰‹ï¼Ÿ 作者：任百鸣 - Dec 10, 2009 ...美国è?”邦食å“?暨è?¯ç‰©ç®¡ç?†å±€ï¼ˆFDA）二零零七年三月å??四日宣布，包括Ambien（美国Zolpiderm的商å“?å??）ã€?Lunesta（å¦å??是Eszopiclone）在内的å??三ç§?å®‰çœ è?¯ï¼Œå¿…须在外包装和 ... 大纪元 Sepracor Announces Tender Offer for 0% Series B Convertible Senior ... - Oct 26, 2009 Sepracor`s currently marketed products in the US include LUNESTA® brand eszopiclone, XOPENEX® brand levalbuterol HCl Inhalation Solution, XOPENEX HFA® brand ... Reuters Hati-hati Efek Obat Tidur Anda - Oct 30, 2009 Pembuat Lunesta (eszopiclone) mengingatkan pasien mengenai efek samping yang umum berupa rasa pahit dan rasa seperti zat kimia di mulut. ... Inilah.com For insomniacs, a sleeping pill for every night; Lunesta is the first... - Jan 17, 2005 Krystal says the entry of eszopiclone into the field of sleep drugs probably will help broaden physicians' views of chronic insomnia and its treatment. ... Pay-Per-View - Los Angeles Times - ProQuest Archiver Insomnia Medications - Insomnia Health Information - NY Times Health - Feb 6, 2008 Eszopiclone (Lunesta) may help improve both sleep maintenance and daytime alertness. Eszopiclone is related to zopiclone (Imovane), which has been used for ... New York Times Learn about Eszopiclone from Consumer Reports Health. - Jan 10, 2008 Eszopiclone is used to treat insomnia (difficulty falling asleep or staying asleep). Eszopiclone is in a class of medications called hypnotics. ... consumerreports.org … Launch Timing for LUNESTA(TM) Brand Eszopiclone for Treatment of … - Apr 1, 2005 Upon publication of the final rule, Sepracor will commence full-scale commercial launch of LUNESTA(TM) brand eszopiclone. Sepracor expects LUNESTA to be ... RedOrbit Eisai Enters into In-licensing Agreement with Sepracor for Eszopiclone... - Jul 27, 2007 Eszopiclone is a non-benzodiazepine type allosteric GABA agonist ... In the United States, eszopiclone received approval from the US Food and Drug ... japancorp.net Eszopiclone, a new sleeping drug, improves sleep among elderly... - Aug 2, 2006 The largest sleep lab-based trial of an insomnia treatment for the elderly shows the effectiveness of eszopiclone. Insomnia is especially common among older ... HealthandAge.com GlaxoSmithKline buys rights to sell sleep drug - Sep 11, 2007 Eszopiclone, which is currently under regulatory review in Europe, has the potential for authorization in as many as 27 EU member countries, according to ... Bizjournals.com Eszopiclone offers multiple benefits in menopausal-associated... - Nov 1, 2005 Eszopiclone (Lunesta, Sepracor), a novel, non-benzodiazepine sleep aid, shows significant value in the treatment of insomnia associated with menopause, ... Free with registration - Formulary - AccessMyLibrary.com … For LUNIVIA(R) (Eszopiclone) Marketing Authorization Application... - Oct 26, 2008 Currently marketed products include LUNESTA® brand eszopiclone, XOPENEX® brand levalbuterol HCl Inhalation Solution, XOPENEX HFA® brand levalbuterol ... Medical News Today - Medical News Today (press release) Long-term Safety of Eszopiclone Confirmed in Repeat Six-Month Study - Sep 29, 2005 Sept. 29, 2005 (San Diego) — Patients can take eszopiclone (Lunesta) for up to six months without experiencing withdrawal symptoms such as rebound insomnia ... Medscape Eszopiclone (Lunesta) With Fluoxetine (Prozac) Improves Comorbid … - May 30, 2005 By Bruce Sylvester. ATLANTA, GA -- May 30, 2005 -- Combination treatment with eszopiclone (Lunesta) and fluoxetine (Prozac) is well tolerated and achieves ... DG News Eszopiclone Plus Escitalopram May Rapidly Improve Insomnia, Anxiety - May 7, 2008 May 7, 2008 — Coadministration of eszopiclone and escitalopram rapidly improved sleep and anxiety in patients with insomnia and generalized anxiety disorder ... Medscape Data Show Sepracor's Eszopiclone Improved Insomnia in Patients with … - Dec 5, 2006 MARLBOROUGH, MA -- December 5, 2006 -- Sepracor Inc. today announces the presentation of results from a Phase IV, 595-patient, double-blind, ... DG News Eszopiclone (Systemic). - Oct 27, 2005 Eszopiclone(ess-ZOP-i-klone)belongs to the group of medicines called central nervous system (CNS) depressants (medicines that make you drowsy or less alert) ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com New Drug Helps Elderly With Insomnia, Study Shows - Jul 28, 2006 The drug eszopiclone, marketed as Lunesta, significantly improved sleep in ... "Eszopiclone was well tolerated and significantly improved sleep onset, ... Medical News Today - Medical News Today (press release) How to take Eszopiclone from Consumer Reports Health. - Jan 10, 2008 ...tell your doctor and pharmacist if you are allergic to eszopiclone or any other medications. tell your doctor and pharmacist what prescription and ... consumerreports.org LUNESTA Phase III/IV Data Presented at 2005 Associated Professional … - Jun 22, 2005 Patients were administered either eszopiclone, zolpidem or placebo for two ... Only eszopiclone 3 mg significantly improved sleep maintenance endpoints (p ... RedOrbit Taking Eszopiclone from Consumer Reports Health. - Jan 10, 2008 Eszopiclone may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:. Some side effects can be serious. ... consumerreports.org Eszopiclone Data Presented at American Psychiatric Association Annual... - May 31, 2006 MARLBOROUGH, MA -- May 31, 2006 -- Sepracor Inc. announced that data from its Phase IIIB/IV studies of Lunesta(TM) brand eszopiclone for the treatment of ... DG News New sleeping aid may open eyes - Feb 13, 2005 Krystal says the entry of eszopiclone into the field of sleep drugs probably will help broaden physicians' views of chronic insomnia and its treatment. ... Seattle Times Data Show Efficacy and Safety of Eszopiclone in Elderly Patients With... - Oct 12, 2006 MARLBOROUGH, MA -- October 12, 2006 -- Sepracor Inc. today announced the publication of results of a large, randomized, double-blind, placebo-controlled, ... DG News Sepracor and Eisai to sell eszopiclone in Japan.(Brief article) - Aug 6, 2007 US research-based pharmaceutical company Sepracor has signed an agreement with Japanese drugmaker Eisai that will focus on the commercialization of the ... $4.95 - Pharma Marketletter - ECNext Sleep aid is first agent not limited to short-term use.(Rx Care) - Jan 24, 2005 Eszopiclone, a Schedule IV controlled substance, will be available in ... "One important factor that distinguishes eszopiclone from zaleplon [Sonata, ... Free with registration - Drug Topics - AccessMyLibrary.com Eszopiclone improves sleep disruptions caused by hot flashes.(clinical... - Mar 1, 2006 Eszopiclone improves sleep disruptions caused by hot flashes.(clinical trials) ... find Clinical Psychiatry News articles. SAN DIEGO -- Perimenopausal women ... Pay-Per-View - Clinical Psychiatry News - HighBeam Research Sepracor files Lunivia MAA with EMEA.(Marketing Approval Application)(... - Aug 6, 2007 Eszopiclone, which is known in the USA as Lunesta, is indicated in that market for the treatment of insomnia. Approval of the MAA would authorize marketing ... $4.95 - Pharma Marketletter - ECNext Insomnia; US FDA approves application for Lunesta brand eszopiclone - Jan 11, 2005 2005 JAN 11 - (NewsRx.com & NewsRx.net) -- The US Food and Drug Administration (FDA) has approved the new drug application (NDA) for Lunesta brand ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones … (Marlborough, MA) Lunesta (eszopiclone) reported positive results... - Jan 1, 2006 Another IIIB/IV study of Sepracor's (Marlborough, MA) Lunesta (eszopiclone) reported positive results for treatment of insomnia in perimenopausal and ... Free with registration - Applied Clinical Trials - AccessMyLibrary.com FDA approves eszopiclone to treat insomnia.(News) - Feb 1, 2005 The Food and Drug Administration has approved a new, nonnarcotic therapy for insomnia, eszopiclone. Most sleep aids are approved for only short-term use of ... Pay-Per-View - Family Practice News - Factiva, from Dow Jones Eszopiclone aids sleep, but has no effect on hot flashes.(Gynecology)... - Apr 15, 2006 Eszopiclone aids sleep, but has no effect on hot flashes.(Gynecology) ... find OB GYN News articles. SAN DIEGO -- Perimenopausal women who took eszopiclone ... Pay-Per-View - OB GYN News - HighBeam Research Eszopiclone Effective at Treating Menopause-Associated Insomnia: … - Oct 5, 2005 By Paula Moyer. SAN DIEGO, CA -- October 5, 2005 -- Women with insomnia that originated in menopause or perimenopause appear to improvement significantly ... DG News Recall: the five most memorable ads.(DTC) - Sep 1, 2007 A little fluorescent moth boosted Sepracor's ads for sleep aid Lunesta (eszopiclone) to the top two in IAG's ranking of the five most-memorable ads for the ... $4.95 - Pharmaceutical Executive - ECNext Sepracor's (SEPR) Reports Results From LUNESTA(R) Study - Sep 3, 2008 Sepracor Inc. (Nasdaq: SEPR) announced the presentation of LUNESTA(R) brand eszopiclone Phase IV study data at the 21st European College of ... StreetInsider.com - StreetInsider.com (subscription) WHAT'S IN THE BOTTLE?, For insomniacs, Lunesta may be dream pill - Jan 25, 2005 Krystal says the entry of eszopiclone into the field of sleep drugs probably will help broaden physicians' views of chronic insomnia and its treatment. ... Pay-Per-View - Newsday - ProQuest Archiver Article: Eszopiclone may put to rest perimenopause sleep disruptions.(... - Apr 15, 2006 Eszopiclone may put to rest perimenopause sleep disruptions.(Women's Health) ... find Family Practice News articles. San Diego -- Perimenopausal women who ... Pay-Per-View - Family Practice News - HighBeam Research Sepracor rises 9.3% on rumors of takeover. - Jun 26, 2006 The USA-based drugmaker is the maker of the successfull sleeping pill Lunesta (eszopiclone) and industry observers note it is an attractive takeover target ... Free with registration - Pharma Marketletter - AccessMyLibrary.com … ; Commercial availability date for eszopiclone treatment for... - Feb 7, 2005 2005 FEB 7 - (NewsRx.com & NewsRx.net) -- Sepracor Inc. (SEPR) announced a revision to the anticipated commercial availability of Lunesta brand eszopiclone ... Pay-Per-View - Health & Medicine Week - Factiva, from Dow Jones … of insomnia-depression study in biological psychiatry of eszopiclon... - May 3, 2006 2006 MAY 3 - (NewsRx.com) -- Sepracor Inc. (SEPR) announced that data from its phase 3b/4, 545-patient study of Lunesta brand eszopiclone in patients with ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones FDA approves eszopiclone to treat insomnia.(News) | Article from... - Feb 1, 2005 FDA approves eszopiclone to treat insomnia.(News) ... find Family Practice News articles. The Food and Drug Administration has approved a new, ... Pay-Per-View - Family Practice News - HighBeam Research … ; Commercial availability date for eszopiclone treatment for... - Feb 11, 2005 2005 FEB 11 - (NewsRx.com & NewsRx.net) -- Sepracor Inc. (SEPR) announced a revision to the anticipated commercial availability of Lunesta brand eszopiclone ... Pay-Per-View - Drug Week - Factiva, from Dow Jones LUNESTA(TM) Second Six-Month Study Data Confirms Findings of First … - Apr 11, 2005 ..."The efficacy and safety results of this trial are consistent with the findings of Sepracor's previously published, six-month study of eszopiclone. ... RedOrbit Adjunctive eszopiclone with fluoxetine for MDD and insomnia.(News... - Jul 1, 2005 New study results for adjunctive eszopiclone (Lunesta) treatment, show statistically significant improvements in time to sleep onset (TSO), wake time after ... Free with registration - Brown University Psychopharmacology... - AccessMyLibrary.com Lunesta Data Presented at 2005 American Psychiatric Association … - May 27, 2005 Averaged over the double-blind period, patients treated with eszopiclone showed ... Adjunctive Eszopiclone With Fluoxetine for MDD and Insomnia: Depression ... Medical News Today - Medical News Today (press release) Side effects of sleep medicines - Sep 11, 2005 ...•Lunesta (eszopiclone): federally approved for long-term use. Drowsiness, dizziness, lightheadedness, difficulty with coordination. ... Pay-Per-View - Detroit Free Press - Factiva, from Dow Jones FDA approves new sleep aid.(News) - Jan 1, 2005 The Food and Drug Administration has approved a new, nonnarcotic therapy for insomnia, eszopiclone. Most sleep aids are approved for only short-term use of ... Free with registration - Clinical Psychiatry News - AccessMyLibrary.com … Launch Timing for LUNESTA(TM) Brand Eszopiclone for Treatment of … - Apr 1, 2005 Sepracor Announces Launch Timing for LUNESTA(TM) Brand Eszopiclone for Treatment of Insomnia. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Eszopiclone Cost Effective in Long-Term Treatment of Insomnia - May 17, 2005 By Sepracor Inc., [RxPG] Sepracor Inc. (Nasdaq: SEPR - News) announces the presentation of results from two analyses designed to assess potential ... RxPG NEWS Eszopiclone may limit sleep disruptions due to hot flashes.(Women's … - Dec 1, 2005 SAN DIEGO -- Perimenopausal women who took eszopiclone for 1 month experienced significant improvements in sleep problems brought on by hot flashes, ... Pay-Per-View - Internal Medicine News - Factiva, from Dow Jones Pilot Study Shows Lunesta (Eszopiclone) Improves Insomnia for... - Nov 22, 2005 MARLBOROUGH, MA -- November 22, 2005 -- Sepracor Inc. announced the presentation of results from its Phase IIIB/IV, 153-patient, 4-week, randomized, ... DG News Article: Comorbid insomnia/depression responds to cotherapy.(Psychiatr... - Sep 1, 2005 ...find Internal Medicine News articles. DENVER -- Coadministration of eszopiclone (Lunesta) and fluoxetine (Prozac) for newly diagnosed major depres... Pay-Per-View - Internal Medicine News - HighBeam Research Memorable brands: increased spending on drug advertising does not … - Aug 1, 2006 Sleep aids Lunesta (eszopiclone) and Ambien (zolpidem) were newcomers on the list, ranking as the fifth and sixth most recalled brands, respectively. ... $9.94 - Pharmaceutical Executive - Alacra Store Eszopiclone may limit sleep disruptions due to hot flashes.(Women's … - Dec 1, 2005 Eszopiclone may limit sleep disruptions due to hot flashes.(Women's Health) ... find Internal Medicine News articles. SAN DIEGO -- Perimenopausal women who ... Pay-Per-View - Internal Medicine News - HighBeam Research Insomnia; US FDA approves application for Lunesta brand eszopiclone - Jan 14, 2005 2005 JAN 14 - (NewsRx.com & NewsRx.net) -- The US Food and Drug Administration (FDA) has approved the new drug application (NDA) for Lunesta brand ... Pay-Per-View - Drug Week - Factiva, from Dow Jones STEPS - June 15, 2005 - American Family Physician - Jun 15, 2005 The duration of action of eszopiclone is approximately eight hours, ... One study3 analyzed the use of eszopiclone for six months in 791 adult patients with ... AAFP News Now NIH consensus panel reviews treatments for insomnia.(Clinical Rounds) - Sep 1, 2005 Only eszopiclone (Lunesta) has been approved for the long-term treatment of insomnia; the other drugs are approved for up to 35 days of use. ... Free with registration - OB GYN News - AccessMyLibrary.com FDA approves a new, nonnarcotic sleep aid.(Psychiatry) | Article from... - Jan 15, 2005 Psychiatry) ... find Internal Medicine News articles. The Food and Drug Administration has approved a new, nonnarcotic therapy for insomnia, eszopiclone. Pay-Per-View - Internal Medicine News - HighBeam Research Article: FDA approves a new, nonnarcotic sleep aid.(Clinical Rounds) ... - Feb 1, 2005 The Food and Drug Administration has approved a new, nonnarcotic therapy for insomnia, eszopiclone. Most sleep aids are approved for only short-term use of ... Pay-Per-View - OB GYN News - HighBeam Research Sepracor's Lunesta now available in the USA.(eszopiclone)(Brief... - Apr 18, 2005 Sepracor's Lunesta (eszopiclone) 1mg, 2mg and 3mg tablets, the first and only prescription or over-the-counter hypnotic, which has been approved by the US ... $4.95 - Pharma Marketletter - ECNext Comorbid insomnia/depression responds to cotherapy.(Psychiatry) - Sep 1, 2005 Also, eszopiclone is part of the newer generation of nonbenzodiazepine ... But sleep improvements in the eszopiclone/fluoxetine group were across the board ... Free with registration - Internal Medicine News - AccessMyLibrary.com Competition coming in sleep disorder mart.(Brief Article) - Sep 26, 2005 The first of these, Sepracor's Lunesta (eszopiclone), hit the market this April and is ... Sanofi-Synthelabo sold the rights to eszopiclone as parat of its ... Pay-Per-View - Pharma Marketletter - Factiva, from Dow Jones Stocks to Watch: BioCurex, Sepracor. - Apr 1, 2005 Sepracor (Nasdaq: SEPR) Announced that the final rule that will designate eszopiclone as a Schedule IV controlled substance will be published in the April 4 ... $4.95 - M2 Presswire - ECNext Article: New hope for insomnia. - Mar 22, 2005 Eszopiclone is manufactured by the pharmaceutical company Sepracor. Originally, Sepracor had given eszopiclone the trade name Estorra but later changed the ... Pay-Per-View - FOCUS: Journal for Respiratory Care... - HighBeam Research Press Release: Preliminary Results Show Improvement for Insomnia … - Jan 12, 2005 Averaged over the double-blind period, patients treated with eszopiclone showed ... In this study, eszopiclone co-administered with fluoxetine resulted in ... Pay-Per-View - PR Newswire - HighBeam Research Details about the employee - Feb 7, 2008 ...dall'antimicotico Lamisil (terbinafina) di Novartis, dall'ipnotico Lunesta (eszopiclone) di Sepracor, e dall'antidepressivo Wellbutrin XL (bupropione a ... Agipress Press Release: Sepracor Announces First Quarter 2005 Operating … - Apr 25, 2005 LUNESTA(TM) brand eszopiclone -- Sepracor began full-scale commercial launch of ... Sepracor Inc. today announced that LUNESTA(TM) (eszopiclone 1 mg, ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Data Show That LUNESTA(TM) May Be Cost Effective for … - May 17, 2005 Cost Effectiveness of Longer-Term Treatment With Eszopiclone 3 mg in Adults With ... Sepracor Inc. today announced that LUNESTA(TM) (eszopiclone 1 mg, ... Pay-Per-View - PR Newswire - HighBeam Research Help for Elderly with Insomnia - Jul 25, 2006 ...“Eszopiclone was well tolerated and significantly improved sleep onset, ... “The finding of less daytime napping associated with eszopiclone treatment in ... PsychCentral.com Treatment options for insomnia.(Disease/Disorder overview)(Clinical … - Aug 15, 2007 Eszopiclone. Eszopiclone, an isomer of zopiclone, is the only hypnotic with FDA ... Eszopiclone has evidence of effectiveness for six months of therapy in a ... $4.95 - American Family Physician - ECNext Two-drug regimen eases anxiety and insomnia.(Psychosomatic Medicine … - Sep 1, 2007 MINNEAPOLIS -- Treatment with both eszopiclone and escitalopram ... At the same time, 294 were randomized to receive 3 mg eszopiclone (Lunesta), ... $4.95 - Clinical Psychiatry News - ECNext … Timing of Commercial Availability for LUNESTA(TM) Brand Eszopiclone... - Jan 11, 2005 Article: LUNESTA(TM) Brand Eszopiclone, Formerly ESTORRA, Approved ... PR Newswire; December 16, 2004 ; 700+ words ... ... Operating Officer at Sepracor. ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: LUNESTA(TM) Second Six-Month Study Data Confirms … - Apr 11, 2005 Drug Application (NDA) for LUNESTA(TM) brand eszopiclone . ... Sepracor Inc. today announced that LUNESTA(TM) (eszopiclone 1 mg, 2 mg and 3 ... prescription ... Pay-Per-View - PR Newswire - HighBeam Research Hypnotic sedative drugs.(Nursing Pharmacology)(Clinical report) - Jun 1, 2007 Eszopiclone is a non-benzodiazepine hypnotic agent approved for treating ... Eszopiclone is metabolized by the hepatic system, and has a half-life of about ... Free with registration - MedSurg Nursing - AccessMyLibrary.com Sleep maintenance shown to decline in old age.(Psychiatry) - Nov 1, 2006 PARIS -- Pooled data from two clinical trials of eszopiclone suggest that ... Adverse events were slightly more common in the elderly on eszopiclone, ... $4.95 - Internal Medicine News - ECNext Sepracor Announces Third Quarter 2006 Operating Results - Oct 26, 2006 LUNESTA(R) brand eszopiclone - In October 2006, Sepracor announced the publication of results of a large, randomized, double-blind, placebo-controlled, ... Genetic Engineering News - Genetic Engineering News (press release) Two-drug regimen eases anxiety and insomnia.(Psychosomatic Medicine … - Sep 1, 2007 ...find Clinical Psychiatry News articles. MINNEAPOLIS -- Treatment with both eszopiclone and escitalopram significantly improved the symptoms of insomn... Pay-Per-View - Clinical Psychiatry News - HighBeam Research Article: Drug device hopeful set for US deals to smooth regulatory … - Aug 13, 2008 Biotech Week; November 12, 2008 ; 549 words ... ... eszopiclone for the treatment of ... Keywords: Drugs, Eszopiclone, Lunesta, Pharmaceutical Business, ... Pay-Per-View - Australasian Business Intelligence - HighBeam Research A Year in Review and Looking Ahead: New Pharmaceutical Treatment … - Dec 8, 2005 Eszopiclone is a nonbenzodiazepine hypnotic (2 mg daily at bedtime, ... [5] Consequently, eszopiclone may cause more morning sedation than other ... Medscape Industry News | November-December 2005 | Sleep Review - Nov 10, 2005 The first 6-month eszopiclone study established the feasibility of the type of longer-term studies needed to guide clinical practice and provided the first ... Sleep Review Sepracor Announces Second Quarter 2005 Operating Results - Jul 19, 2005 LUNESTA brand eszopiclone - During the quarter, Sepracor began full-scale commercial launch of LUNESTA 1 mg, 2 mg and 3 mg tablets for the treatment of ... RedOrbit SEPRACORE REPORTS NET INCOME OF $11.3 MIL FOR 2ND QTR … - Sep 1, 2006 LUNESTA brand eszopiclone - During the second quarter of 2006, Sepracor announced the ... The Regimen of Eszopiclone Sleep Satisfaction Trial (RESST), ... Entrepreneur SEPRACOR REPORTS 2ND QTR 2005 NET LOSS OF $7.4 MILLION. - Sep 1, 2005 LUNESTA brand eszopiclone - During the quarter, Sepracor began full-scale commercial launch of LUNESTA 1 mg, 2 mg and 3 mg tablets for the treatment of ... Entrepreneur Sleeping problems in mood, anxiety disorders: make sure that primary ... - Feb 1, 2006 There is an increasing number of hypnotics--eszopiclone (Lunesta), ramelteon (Rozerem), and zolpidem extended release (Ambien CR) were added last year--to ... Free with registration - Clinical Psychiatry News - AccessMyLibrary.com Insomnia.(DRUG UPDATE) - Jul 1, 2006 Eszopiclone and extended-release zolpidem (Ambien CR) have no time restrictions on ... Eszopiclone, if used infrequently, is probably low risk in pregnancy. ... Free with registration - Internal Medicine News - AccessMyLibrary.com Sepracor Announces Fourth Quarter and Full Year 2005 Results; … - Jan 31, 2006 LUNESTA(TM) brand eszopiclone - "The launch of LUNESTA in April 2005 marked a turning point for Sepracor. LUNESTA is our second commercialized product ... RedOrbit Article: Psychiatric drug OK'd for youths; FDA approval seen as guide... - Aug 23, 2007 If approved by the FDA, eszopiclone could provide ... compound that, if approved by the FDA, could represent a true advance ... ... Pay-Per-View - Washington Times - HighBeam Research Sepracor Inc. and Bial Announce Exclusive Licensing Agreement for … - Jan 2, 2008 Currently marketed products include LUNESTA brand eszopiclone, XOPENEX([R]) brand levalbuterol HCl Inhalation Solution, XOPENEX HFA([R]) brand levalbuterol ... Free with registration - Business Wire - AccessMyLibrary.com THE HEALTHY TRAVELER; New weapons in travelers' round-the-clock … - Apr 23, 2006 ..."Lunesta (eszopiclone) provides seven or eight hours. Sonata (zaleplon) is better when a person has limited time to sleep, say five or six hours. ... Pay-Per-View - Los Angeles Times - ProQuest Archiver Sepracor Inc. Announces Third Quarter 2007 Results and Planned … - Oct 30, 2007 LUNESTA brand eszopiclone revenues grew to $160.9 million in the third quarter of 2007 compared to $141.6 million for the same quarter in 2006, ... Free with registration - Business Wire - AccessMyLibrary.com Schedules of Controlled Substances: Placement of Zopiclone Into … - Apr 4, 2005 Eszopiclone will be marketed as a prescription drug product for the treatment of insomnia. On January 18, 2005, the Acting Assistant Secretary for Health, ... Pay-Per-View - Federal Register - Factiva, from Dow Jones Many insomnia drugs in therapeutic pipeline.(Psychiatry) | Article... - Nov 1, 2005 Of the FDA-approved drugs, only two--the benzodiazepine receptor agonist eszopiclone (Lunesta) and ramelteon--were approved ... Eszopiclone has been ... ... Pay-Per-View - Internal Medicine News - HighBeam Research Sepracor Announces First Quarter 2006 Results. - Apr 25, 2006 LUNESTA(TM) brand eszopiclone - LUNESTA is indicated for the treatment of sleep onset and/or sleep maintenance insomnia and is available by prescription in ... $4.95 - Business Wire - ECNext Article: Insomnia.(Drug Update) - Skin & Allergy News | HighBeam … - Sep 1, 2006 Eszopiclone and extended-release zolpidem (Ambien CR) have no time restrictions on ... Eszopiclone, if used infrequently, is probably low risk in pregnancy. ... Pay-Per-View - Skin & Allergy News - HighBeam Research Sepracor Inc. Announces Second Quarter 2007 Results and Significant … - Jul 27, 2007 Ltd. for development and commercialization of eszopiclone (marketed as ... LUNESTA([R]) brand eszopiclone revenues grew to $143 million in the second ... Free with registration - Business Wire - AccessMyLibrary.com Press Release: Memory Pharmaceuticals Announces Six Abstracts … - Nov 10, 2008 The data to be presented today includes the following: Eszopiclone in Non-Elderly and Elderly Patients with Chronic. See all results Or, try our Advanced ... Pay-Per-View - PR Newswire - HighBeam Research Sepracor Inc. and Eisai Co. Ltd. Announce Partnership for Development... - Jul 26, 2007 Ltd. for the development and commercialization of Sepracor's eszopiclone product, ... Currently marketed products include LUNESTA brand eszopiclone, ... Genetic Engineering News - Genetic Engineering News (press release) Antidepressants may extend need for hypnotics.(Adult Psychiatry) |... - Oct 1, 2008 Hypnotics are more reliable ... fatigue, although a hypnotic may be needed as ... increasing number of hypnotics--eszopiclone ... were added last year--to ... Pay-Per-View - Clinical Psychiatry News - HighBeam Research Press Release: Depth of MedImmune's Respiratory Disease Research … - May 15, 2008 The data to be presented today includes the following: Eszopiclone in Non-Elderly and Elderly Patients with Chronic. See all results Or, try our Advanced ... Pay-Per-View - PR Newswire - HighBeam Research Sepracor Announces Third Quarter 2005 Operating Results. - Oct 25, 2005 LUNESTA(TM) brand eszopiclone - LUNESTA is a non-narcotic non-benzodiazepine indicated for the treatment of insomnia in patients who experience difficulty ... Free with registration - Business Wire - AccessMyLibrary.com Sepracorä¸Žè‘›å…°ç´ å?²å…‹è¾¾æˆ?å‚¬çœ è?¯è?¥é”€å??è®® - Sep 11, 2007 Eszopicloneç›®å‰?æ£ä¸ºèŽ·å¾—欧盟上市批准而接å?—欧洲è?¯å“?管ç?†å±€(EMEA)的评估。 该è?¯åœ¨ç¾Žå›½ 是以Lunesta为å“?牌å??è?¥é”€çš„。 æ–°æµªå£°æ˜Žï¼šæœ¬ç‰ˆæ–‡ç« å†…å®¹çº¯å±žä½œè€…ä¸ªäººè§‚ç‚¹ï¼Œä»…ä¾›æŠ•èµ„ ... 新浪网 Sepracor Announces Second Quarter 2006 Operating Results - Jul 21, 2006 LUNESTA brand eszopiclone - During the second quarter of 2006, Sepracor announced the publication of results of a study in which LUNESTA was administered to ... Genetic Engineering News - Genetic Engineering News (press release) Article: You May Want to Sleep on It; Enter the Next 'Miracle' Drug:... - Jan 18, 2005 Article: LUNESTA(TM) Brand Eszopiclone, Formerly ESTORRA, Approved ... PR Newswire; December 16, 2004 ; 700+ words ... ... approved the New Drug Application ... Pay-Per-View - Washington Post - HighBeam Research Brand Names/Synonyms: Eszopiclone is also known by the following brand names and/or synonymsEsopiclone; Estorra; Eszopiclone; Eszopiclone [Usan:Inn]; Eszopiclone [Usan]; Lunesta Drug Category: Eszopiclone is categorized under the following by the FDA: Hypnotics and Sedatives; ATC:N05CF01 Dosage Forms: Tablet Absorption: Rapidly absorbed following oral administration Interactions: [an error occurred while processing this directive] Chemical IUPAC Name: [8-(5-chloropyridin-2-yl)-7-oxo-2,5,8-triazabicyclo[4.3.0]nona-1,3,5-trien-9-yl] 4-methylpiperazine-1-carboxylate |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |